Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
Wearing-off phenomenon that complicates levodopa therapy of Parkinson's disease has been attributed to a reduction in striatal dopamine storage due to the progressive degeneration of presynaptic dopaminergic terminals. To determine whether postsynaptic mechanisms also contribute to these response fluctuations, the duration of the antiparkinsonian response in parkinsonian patients grouped by disease severity was compared following discontinuation of a steady-state optimal-dose infusion of apomorphine. Although the plasma half-life of this dopamine receptor agonist remained constant, its mean efficacy half-time declined from 66 minutes in early, levodopa-naive patients to 33 minutes in advanced, complicated parkinsonians (p < 0.005). Since the motor effects of apomorphine do not depend on the presence of dopaminergic terminals, changes at the postsynaptic level undoubtedly contribute to the diminished response duration. The only slightly greater attenuation of levodopa's motor effects observed previously under similar conditions suggests these postjunctional alterations, possibly involving relatively plastic striatal dopaminoceptive systems, account for most of the shortening in the duration of levodopa action that underlie wearing-off fluctuations.
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892.
D
D
Bravi
M M
MM
Mouradian
J W
JW
Roberts
T L
TL
Davis
Y H
YH
Sohn
T N
TN
Chase
D001058:Apomorphine / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D003342:Corpus Striatum / Q000503:physiopathology; D004298:Dopamine / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006207:Half-Life; D006801:Humans; D007980:Levodopa / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D009068:Movement / Q000187:drug effects; D009473:Neuronal Plasticity; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D012720:Severity of Illness Index
D011954:Receptors, Dopamine; D007980:Levodopa; D001058:Apomorphine; D004298:Dopamine